Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (6426Q)

TIDMHCM

RNS Number : 6426Q

Hutchison China Meditech Limited

07 June 2018

Grant of Share Options under Share Option Scheme

London: Thursday, June 7, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").

Chi-Med granted 36,936 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

 
 Date of grant                      :   June 6, 2018 
 Exercise price of share options    :   GBP41.66 per Ordinary Share 
  granted 
 Number of share options granted    :   36,936 (each share option shall 
                                         entitle the holder thereof to subscribe 
                                         for one Ordinary Share) 
 Closing market price of Ordinary   :   GBP41.40 per Ordinary Share 
  Shares on the date of grant 
 Validity period of the share       :   From June 6, 2018 to June 5, 2028 
  options 
 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, Corporate Finance 
 & Development                                       [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson             [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, Solebury Trout                           [phone] (Mobile)  [e-mail] 
Susan Duffy, Solebury Trout                          [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Xuan Yang, Solebury Trout                            [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson                  [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                          [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOEUGUWAQUPRURM

(END) Dow Jones Newswires

June 07, 2018 05:00 ET (09:00 GMT)